Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:Cetuximab in preoperative treatment of rectal cancer - term outcome of the XERT trial
Avtorji:ID Velenik, Vaneja (Avtor)
ID Ocvirk, Janja (Avtor)
ID Oblak, Irena (Avtor)
ID Anderluh, Franc (Avtor)
Datoteke:.pdf PDF - Predstavitvena datoteka, prenos (332,74 KB)
MD5: 8459228AE348EEB862238B9C99B4A5AE
 
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo OI - Onkološki inštitut Ljubljana
Povzetek:Preoperative capecitabine-based chemoradiotherapy (CRT) is feasible for the treatment of resectable locally advanced rectal cancer (LARC). To try to improve efficacy, we conducted a phase II studz in which the epidermal growth factor receptor-targeting monoclonal antibody cetuximab was added to capecitabine-based CRT. The results for long-term survival and for an analysis investigating the relationship between survival and patient and disease characteristics, including tumour KRAS mutation status, and surgery type, are presented. Patients with resectable LARC received capecitabine (1250mg/m2 twice daily, orally) for 2 weeks followed by cetuximab alone (400 mg/m2 for 1 week) and then with CRT (250 mg/m2/week) comprising capecitabine (825 mg/m2 twice daily) and radiotherapy to the small pelvis (45 Gz in 25 1.8-Gz fractions), five dazs a week for five weeks. Surgery was conducted six weeks following CRT, with post-operative chemotherapy with capecitabine (1250 mg/m2 twice daily for 14 days every 21 days) three weeks later. Forty-seven patients were enrolled and 37 underwent treatment. Twenty-eight of the patients (75.7%) had T3N+ disease. Thirty-six patients were evaluable for efficacy. The median follow-up time was 39.0 months (range 5.0-87.0). The three-year local control, disease-free survival, relapse-free survival and overall survival rates were 96.9% (95% CI 90.0-100), 72.2% (57.5-86.9), 74.3% (95% CI 59.8-88.8) and 68.1% (95% CI 36.7-99.4), respectively. There was no significant association between survival and gender, age, tumour location in the rectum, type of surgery, pathological T or N status, tumour regression grade or tumour KRAS mutation status, although sample sizes were small. Preoperative cetuximab plus capecitabine-based CRT was feasible in patients with resectable LARC and was associated with an impressive three-year local control rate. The use of tumour KRAS mutation status as a biomarker for the efficacy of cetuximab-based regimens in this setting requires further investigation.
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Datum objave:01.01.2012
Založnik:Association of Radiology and Oncology
Leto izida:2012
Št. strani:str. 252-257, V
Številčenje:Vol. 46, no. 3
Izvor:Ljubljana
PID:20.500.12556/DiRROS-18500 Novo okno
UDK:616.35-006.6-08
ISSN pri članku:1318-2099
DOI:10.2478/v10019-012-0030-2 Novo okno
COBISS.SI-ID:1362299 Novo okno
Avtorske pravice:by Authors
Opomba:Soavtorji: Janja Ocvirk, Irena Oblak, Franc Anderluh;
Datum objave v DiRROS:21.03.2024
Število ogledov:704
Število prenosov:138
Metapodatki:XML DC-XML DC-RDF
:
VELENIK, Vaneja, OCVIRK, Janja, OBLAK, Irena in ANDERLUH, Franc, 2012, Cetuximab in preoperative treatment of rectal cancer - term outcome of the XERT trial. Radiology and oncology [na spletu]. 2012. Vol. 46, no. 3, p. 252–257, v. [Dostopano 11 april 2025]. DOI 10.2478/v10019-012-0030-2. Pridobljeno s: https://dirros.openscience.si/IzpisGradiva.php?lang=slv&id=18500
Kopiraj citat
  
Objavi na:Bookmark and Share



Podobna dela iz ostalih repozitorijev:
  1. Osnovne značilnosti raka jajčnikov
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:Radiology and oncology
Skrajšan naslov:Radiol. oncol.
Založnik:Slovenian Medical Society - Section of Radiology, Croatian Medical Association - Croatian Society of Radiology
ISSN:1318-2099
COBISS.SI-ID:32649472 Novo okno

Sekundarni jezik

Jezik:Slovenski jezik
Naslov:Predoperativna radioterapija, kapecitabin in cetuksimab pri zdravljenju lokalno napredovalnega raka danke
Ključne besede:novotvorbe danke, radioterapija, mutacije, preživetje, bolniki


Nazaj